Gabapentin and Substance Use: Unmasking the Truth About Misuse and Treatment
"Is gabapentin the answer to treating substance use disorders, or a hidden risk? Belgian study reveals surprising insights into gabapentin use and its potential for abuse."
Gabapentin, a medication primarily licensed in the European Union for neuropathic pain and epilepsy, has also found its way into the treatment landscape for substance use disorders. While it holds promise for some, concerns linger about its potential for misuse, particularly among individuals already grappling with addiction.
The burning question is: Are individuals in treatment for substance use disorders at a higher risk of misusing gabapentin? Do they exceed recommended dosages in their pursuit of relief or altered states? A recent study in Belgium sought to shed light on this issue, providing valuable insights into the utilization patterns of gabapentin within this specific population.
This article delves into the findings of that Belgian study, dissecting its methodology, results, and conclusions to provide a comprehensive understanding of gabapentin's role in substance use disorder treatment. We will explore whether the study found evidence of widespread misuse, and what the implications are for prescribing practices and patient safety.
A Commonly Prescribed Drug With a Growing Risk Profile
Gabapentin is a prescription medication approved to treat partial seizures, nerve pain after shingles, and restless legs syndrome, and it is also widely used off-label, according to Drugs.com. Statista has tracked the total annual number of gabapentin prescriptions in the U.S. from 2004 through 2023, with figures reported in millions. SingleCare's statistics roundup similarly documents the drug's high prescription volume and catalogues the frequency of reported side effects. MedlinePlus adds that gabapentin carries important special precautions, underscoring why such widespread use deserves careful attention. The scale of prescribing documented across these sources helps explain why the drug has drawn growing scrutiny around misuse.
Careful Titration In, Careful Tapering Out
The accepted approach to starting gabapentin relies on gradual dose titration designed to minimize side effects while reaching therapeutic levels, as Doctronic describes. A widely cited standard schedule begins at 300 mg and increases by 300 mg per day over the first three days, to a total of 900 mg per day, according to a clinical protocol published on PMC. Pain Spa reports a consistent starting pattern of 300 mg at night on the first day in postherpetic neuralgia and similar neuropathic pain conditions. Stopping the drug presents its own challenges: Ridgefield Recovery notes that reducing the dose too quickly carries withdrawal risks, so patients are advised to taper gradually, ideally with treatment support. This contrast between careful ramp-up and careful ramp-down highlights why abrupt discontinuation of gabapentin can be unsafe.
From a GABA Theory to a Widely Used Painkiller
Gabapentin was developed as an anticonvulsant — a derivative of the inhibitory neurotransmitter GABA — and is best known under the brand name Neurontin, according to Wikipedia. Its primary uses have long been partial seizures of epilepsy and neuropathic pain, though the Recovery Village notes it has also been used in the management of withdrawal symptoms. Health Signal Pro explains that the drug's name is a fossil of the original GABA-based theory, an idea that stuck because gabapentin was already established by the time researchers understood its true mechanism. More recent attention has shifted to its downside: MedShadow reports that gabapentin treats nerve pain and epilepsy but carries addiction risks, highlighting a growing threat of gabapentin abuse. The arc from epilepsy drug to nerve-pain mainstay to object of misuse concerns frames the drug's complicated modern reputation.
Decoding the Belgian Gabapentin Study: Methodology and Key Findings
The Belgian study, a cross-sectional analysis spanning from 2011 to 2014, meticulously examined data from two key sources: the Treatment Demand Indicator (TDI) database and the InterMutualistic Agency (IMA) database. By linking these datasets at the individual level, researchers were able to track gabapentin purchases among individuals undergoing treatment for substance use disorders.
- Selection of subjects based on their first registration in the TDI database between 2011 and 2014, without exclusions based on nationality or age.
- Linkage with the IMA database to gather information on health service and medication use.
- Matching each subject with four comparators from the general population who were not in specialized treatment, based on age, sex, and place of residence.
- Quantification of gabapentin amounts between consecutive purchases as a proxy for potential abuse, defined as exceeding the maximum approved dose of 3600 mg/day.
New Science on Mechanism, Pregnancy, and Off-Label Use
Recent research is refining the picture of how gabapentin works and whom it affects. Medical Xpress reports that researchers at UC San Francisco have shown for the first time how gabapentin acts inside cells, a finding that could open the door to new, more effective treatments for conditions such as epilepsy. In pregnancy research, a PLOS Medicine study evaluated gabapentin exposure in early, late, and both early and late pregnancy, examining outcomes including preeclampsia, preterm birth, small-for-gestational-age infants, and NICU admission. Pain News Network notes that although gabapentin was originally developed to prevent epileptic seizures, it is now commonly prescribed off-label as an alternative to opioids for pain management — and that researchers have long been concerned about its effects on brain neurotransmitters. Together these threads show a drug whose mechanism, safety profile, and real-world use are all still being actively studied.
Between Patient Support and Corporate Scandal
Perspectives on gabapentin diverge sharply. On one side, patients report life-changing relief: a Mayo Clinic forum participant living with neuropathy says that without gabapentin they would have been at risk of self-harm, and urges against public criticism of the drug for fear it could lead to tighter prescribing restrictions. On the other side, the drug's commercial history is troubled — Medscape reports that Pfizer was heavily criticized for off-label marketing and in 2004 pleaded guilty to criminal fraud, paying close to $430 million to settle charges that included defrauding Medicaid over illegal promotion of gabapentin. Clinical expectations can also be limited: the Villa Treatment Center notes that gabapentin modulates calcium channels rather than directly enhancing GABAergic transmission, which limits its acute efficacy for panic attacks compared with established alternatives. The drug's reputation is thus a mix of genuine patient benefit, documented marketing misconduct, and modest efficacy in some off-label uses.
How Gabapentin Compares With Its Alternatives
Gabapentin is frequently compared with other drugs used for nerve pain, seizures, and related conditions. Drugs.com offers side-by-side comparisons of medications covering uses, ratings, cost, side effects, and interactions, along with information on brand versus generic differences. Lyrica (pregabalin) is one of the most common comparison points: Medical News Today notes that the two drugs treat some seizures and nerve pain, and it details both their similarities and differences. SingleCare similarly lists top gabapentin and Neurontin alternatives and compares them, including average retail price without insurance. Comparisons also extend beyond the gabapentinoid class — GoKick evaluates hydroxyzine versus gabapentin specifically for sleep, illustrating how the drug's off-label uses factor into prescribing decisions.
The Verdict: Gabapentin Abuse in Belgium, a Limited Concern?
Despite the increased likelihood of gabapentin use among individuals in substance abuse treatment, the Belgian study found no evidence of widespread, regular abuse exceeding approved dosage. The data suggests that gabapentin procurements occur primarily through legitimate channels like pharmacies and hospitals, not through illicit means like online purchases or local drug dealers.
Experts Weigh Benefit, Timing, and Risk
Clinical experts generally regard gabapentin as effective and well tolerated for certain conditions — one published review offers the expert opinion that the drug appears effective and well tolerated in treating chronic cough and other sensory neuropathic disorders. Realistic expectations matter, though: SingleCare notes that gabapentin can take anywhere from a few hours to several weeks to work, depending on the reason it is being used. The drug's reach extends beyond humans — Forbes Advisor notes that veterinarians also use oral gabapentin for chronic nerve and joint pain in cats and to reduce fear and anxiety related to travel or veterinary visits, with both liquid and capsule forms available. Yet experts also flag the drug's accessibility as a danger: The Hearty Soul reports that a specialist said gabapentin's ready availability is where much of the risk lies, making it available to be abused and tying it to the opioid crisis. That combination of genuine efficacy, slow onset, and widespread availability captures why gabapentin inspires both clinical enthusiasm and caution.
A Bullish Market Shadowed by New Safety Questions
Market forecasts for gabapentin point in one direction: growth. Market Research Future projects the gabapentin market will reach USD 4.577 billion by 2035, representing a 5.9% compound annual growth rate. A separate price outlook is consistent, describing the 2026 outlook as moderately bullish, driven by rising healthcare demand, stable pharmaceutical consumption, and fluctuating feedstock prices. Meanwhile, clinical and legal questions are accumulating: one study assessed incident gabapentin prescribing in relation to opioid use, using Cox regression to examine incidence rate ratios while exploring the influence of chronic conditions and long-term SSRI use, along with the amount and duration of future gabapentin use. On the legal side, AllAboutLawyer reports that no active gabapentin cases remain and settlements have been closed since 2008 — yet a new study suggesting a link between gabapentin and cognitive decline that increases with the number of refills, and is more pronounced in people aged 35 to 49, is raising fresh questions about future litigation.
Beyond Pain: Off-Label Roles and Systemic Pressures
Gabapentin's role now extends well beyond seizure and nerve-pain care. Ria Health describes it as an anti-seizure medication that can also ease alcohol withdrawal symptoms and help reduce alcohol consumption, giving it a place in addiction treatment. Its mechanism sets it apart from most psychiatric drugs — NeuroLaunch notes that gabapentin does not touch the neurotransmitter systems most psychiatric medications target, which is both part of its appeal and the source of its distinctive cognitive effects on mental function and memory. At the system level, Consegic Business Intelligence identifies key market challenges including side effects such as dizziness and fatigue, which may hurt patient compliance, as well as concerns about potential misuse that have led to stricter regulations in some regions. These threads connect the drug's expanding off-label uses, its unusual pharmacology, and the regulatory and compliance pressures shaping how it is prescribed.
Real Patients, Real Consequences
Behind the statistics are individual stories and concrete clinical harms. The Times of India reports on a study suggesting that gabapentin, a popularly prescribed pain drug, may increase the risk of dementia by up to 40 percent, while noting that the drug was FDA-approved in 1993 to control partial seizures and is used to treat nerve pain, epilepsy, and restless legs syndrome. Bestie Paws documents a medical case report of a patient on high-dose gabapentin combined with opioids who developed acute respiratory failure and encephalopathy when gabapentin was suddenly stopped in the hospital. An OSC podcast episode explores how a viral study's claims about gabapentin affect everyday patients and the wider world, underscoring the real-world stakes of the research. These accounts show a drug whose benefits and harms land on real people — sometimes both at once.